Vaccines are a type of immunotherapy. Unlike vaccines to protect us from disease, cancer treatment vaccines are for people who already have cancer. Therapeutic cancer vaccines train your body to protect itself against its own damaged or abnormal cells — including cancer cells. These vaccines expose your immune system to molecules associated with cancer that enables the immune system to recognize and destroy cancer cells.
Cancer vaccines currently in use are prostate cancer vaccine (sipuleucel-T  - Provenge®), melanoma vaccine ( T-VEC  - Imlygic®) and Cuban lung cancer vaccines ( Racotumumab – Vaxira and CIMAvax-EGF).
In our clinic, we administer Cuban lung cancer vaccines and dendritic cancer vaccines in eligible patients.
GM3(Neu5Gc) ganglioside is a cancer antigen structure found in cancer cells but not in healthy cells. The Racotumumab (Vaxira) cancer vaccine developed in Cuba may be effective against cancers that carry this protein. The main goal of the Racotumumab cancer vaccine is to increase the immune system's response to GM3(Neu5Gc) ganglioside protein on the surface of cancer cells, allowing them to bind to it and subsequently identify and destroy the cancer cell. Because GM3(Neu5Gc) ganglioside protein is not present in normal healthy cells, the vaccine only affects cancer cells and does not affect normal cells.
Cancers that contain the GM3(Neu5Gc) ganglioside protein targeted by Racotumumab include (1-9):
Small cell lung cancer
Breast cancer
Esophageal cancer
Stomach cancer
Colon cancer
Rectal cancer
Pancreatic cancer
Liver cancer
Kidney cancer
Bladder cancer
Testicular cancer
Uterine cancer
Prostate cancer
Thyroid cancer
Sarcomas
Wilms tumor
Ewing sarcoma
Neuroblastoma
The anti-EGF vaccine (CIMAvax-EGF) is a cancer vaccine developed in Cuba. Racotumumab and anti-EGF cancer vaccines have been approved for use in various countries for cancer treatment. The Racotumumab and anti-EGF cancer vaccines are approved for use in the treatment of advanced-stage non-small cell lung cancer that has responded to chemotherapy or radiotherapy (10). In suitable patients, we can prescribe and use the Racotumumab vaccine. Clinical studies and case presentations indicate that the Racotumumab vaccine may be effective in other types of cancer and it is expected to be approved for use in these cancers in the future. One of the main advantages of Cuban cancer vaccines is that they can extend the lives of cancer patients without significant side effects and provide long-term, high-quality life for some patients.

Reference:
1. Marquina G , Waki H , Fernandez LE , et al. Gangliosides expressed in human breast cancer. Cancer Res 1996;56:516551–71 .
2. Oliva JP , Valdes Z , Casaco A , et al. Clinical evidences of GM3 (NeuGc) ganglio- side expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc. Breast Cancer Res Treat 2006;96:115–21 .
3. Carr A , Mullet A , Mazorra Z , et al. A mouse IgG1 monoclonal antibody spe- cific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 2000;19: 241–7.
4. Zhong Y , Wu Y , Li C , et al. N-Glycolyl GM3 ganglioside immunoexpression in oral mucosal melanomas of Chinese. Oral Dis 2012;18:741–7 . [16] Blanco R , Rengifo E , Cedeno M , et al. Immunoreactivity of the 14F7 Mab raised against N-Glycolyl GM3 ganglioside in epithelial malignant tumors from digestive system. ISRN Gastroenterol 2011;2011:645641.
5. Blanco R , Quintana Y , Blanco D , et al. Tissue reactivity of the 14F7 Mab raised against N-Glycolyl GM3 ganglioside in tumors of neuroectodermal, mesoder- mal, and epithelial origin. J Biomark 2013;2013:602417.
6. Scursoni AM , Galluzzo L , Camarero S , et al. Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an at- tractive vaccine target for aggressive pediatric cancer. Clin Dev Immunol 2011;2011:245181.
7. Blanco R , Dominguez E , Morales O , et al. Prognostic significance of N-Glycolyl GM3 ganglioside expression in non-small cell lung carcinoma patients: new evidences. Patholog Res Int 2015;2015:132326.
8. Hayashi N , Chiba H , Kuronuma K , et al. Detection of N-glycolyated ganglio- sides in non-small-cell lung cancer using GMR8 monoclonal antibody. Cancer Sci 2013;104:43–7.
9. Labrada M, Dorvignit D, Hevia G, et al. GM3(Neu5Gc) ganglioside: an evolution fixed neoantigen for cancer immunotherapy. Semin Oncol. 2018 Jan;45(1-2):41-51.
10. Hernández AM, Vázquez AM. Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer. Expert Rev Vaccines. 2015 Jan;14(1):9-20.